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BACKGROUND/OBJECTIVES: Obese subjects are commonly deﬁcient in several micronutrients. Weight loss, although
beneﬁcial, may also lead to adverse changes in micronutrient status and body composition. The objective of the
study is to assess changes in micronutrient status and body composition in obese individuals after a dietary weight
loss program.
SUBJECTS/METHODS: As part of a dietary weight loss trial, enrolling 192 obese patients (body mass index 430kg/m
2) with
knee osteoarthritis (450 years of age), vitamin D, ferritin, vitamin B12 and body composition were measured at baseline and
after 16 weeks. All followed an 8-week formula weight-loss diet 415--810kcal per day, followed by 8 weeks on a hypo-
energetic 1200kcal per day diet with a combination of normal food and formula products. Statistical analyses were based on
paired samples in the completer population.
RESULTS: A total of 175 patients (142 women), 91%, completed the 16-week program and had a body weight loss of 14.0kg
(95% conﬁdence interval: 13.3--14.7; Po0.0001), consisting of 1.8kg (1.3--2.3; Po0.0001) lean body mass (LBM) and 11.0kg
(10.4--11.6; Po0.0001) fat mass. Bone mineral content (BMC) did not change (-13.5g; P¼0.18), whereas bone mineral density
(BMD) increased by 0.004g/cm
2 (0.001--0.008g/cm
2; P¼0.025). Plasma vitamin D and B12 increased by 15.3nmol/l (13.2--17.3;
Po0.0001) and 43.7pmol/l (32.1--55.4; Po0.0001), respectively. There was no change in plasma ferritin.
CONCLUSIONS: This intensive program with formula diet resulted in increased BMD and improved vitamin D and B12 levels.
Ferritin and BMC were unchanged and loss of LBM was only 13% of the total weight loss. This observational evidence supports
use of formula diet-induced weight loss therapy in obese osteoarthritis patients.
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INTRODUCTION
Obese subjects often show micronutrient deﬁciencies.
1- -5 The
reason for this is complex. Obesity reduces the bioavailability of
several vitamins and there may be an alteration in nutrient
metabolism. Furthermore, the quality of ingested foods may be
poor.
2 Obesity and being overweight represent a rapidly growing
threat to the health of populations in an increasing number of
countries.
6 Positive energy balance deriving from excessive food
intake in relation to energy expenditure is the pathophysiological
basis of obesity in most cases. Weight loss is expected to result in
a signiﬁcant reduction in risk of the majority of these comorbid
conditions.
7 Weight loss has, however, also been associated with
(a potentially harmful) loss of muscle mass and bone in obese
individuals.
8
A variety of weight loss methods are available today, including
diet therapy approaches such as low-calorie diets and lower-fat
diets, change in physical activity patterns, behavior therapy
techniques, pharmacotherapy, surgery and combinations of these
techniques. Among these, bariatric surgery is the most effective
but it is found to aggravate the insufﬁcient state of several
micronutrients.
9 As obesity and micronutrient deﬁciencies are
related to and associated with increased risk of morbidity, one
must consider the nutritional value and capacity of weight-loss
treatments to secure adequate amounts of nutrients and prevent
detrimental effects while losing weight. In the current study, we
used a prospective cohort of sedentary obese knee osteoarthritis
patients, who completed a weight loss trial to look at the effect
of a formula low-energy diet on micronutrient status, that is,
vitamin D, vitamin B12, ferritin as well as on body composition.
Clinically, osteoarthritis causes painful joints and is a leading cause
of impaired mobility in the elderly; most patients with sympto-
matic knee osteoarthritis have limitations in function that prevent
them from engaging in their usual activities.
10
Our objective was to assess and evaluate changes in
micronutrient status (vitamin D, B12 and ferritin) and body
composition in obese knee osteoarthritis patients after 8 weeks
of low-energy diet followed by 8 weeks of a hypo-energetic diet,
including two formula diet products daily.
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www.nature.com/PARTICIPANTS AND METHODS
The results presented in this paper are from a prospective cohort of 192
well-characterized obese knee osteoarthritis patients over 50 years of age.
In this study, we assessed micronutrient status and body composition,
including total body bone mineral content (BMC) and bone mineral density
(BMD) in the completer population, that is, all the participants who entered
and completed the weight loss trial, using data from the baseline and
16-week assessment. The CAROT study (‘Inﬂuence of weight loss or
exercise on CARtilage in Obese knee osteoarthritis patients Trial’) was a
randomized controlled trial designed to answer the question of how to
maintain the anticipated symptomatic effect sustaining weight loss for 1
year (ClinicalTrials.gov identiﬁer: NCT00655941). All the participants initially
received dietary support for 16 weeks, in order to loose body weight and
obtain a clinically important reduction in pain, improvement in physical
function and mobility.
11 The current study is looking into the nutritional
beneﬁt and harm following the 16-weeks diet scheme.
Setting
Participants included in this pragmatic trial were recruited between
November 2007 and August 2008 from the outpatient clinic at the
Department of Rheumatology, Frederiksberg Hospital, Frederiksberg,
Denmark, through advertisements in newspapers and on the website of
the Parker Institute. Additionally, local general practitioners were informed
about the possibility of assigning patients to the project.
Participants
Individuals who were 450 years of age with conﬁrmed knee osteoarthritis
according to standing radiographs were eligible for inclusion,
12 and obese
as deﬁned by a body mass index (BMI) X30kg/m
2. Exclusion criteria were:
lack of motivation to loose weight, inability to speak Danish, planned
antiobesity surgery, total knee alloplasty and receiving pharmacological
therapy for obesity. In all, 192 patients were enrolled in the trial. The
participants were asked not to change any medication or nutritional
supplement during the study. The study was approved by the ethics
committee of the Capital Region of Denmark (H-B-2007--088) and all
participants signed an informed consent form.
Interventions
The ﬁrst phase of the study consisted of an 8-week weight reduction
program where the participants were using either an all-provided very low
energy diet (VLED) with 420- -554kcal/d (1743- -2327kJ/d) or a low energy
diet (LED) with 810kcal/d (3402kJ/d) in a supervised dietary program
(products provided by the Cambridge Diet, the Cambridge Weight plan,
UK). Participants were weighed on a decimal scale and given nutritional
and dietetic instructions by an experienced dietician in weekly sessions
of 11
2--2h. The VLED program consisted of powdered formula mixture
dissolved in water. Women below a height of 173cm were given three
sachets a day E415kcal per day (1743kJ per day, 43.2g protein). Men and
women taller than 173cm were given four sachets a day E520kcal per
day (2327kJ per day, 57.6g protein). The LED program consisted of
powdered formula mixture dissolved in skimmed milk and water.
Participants were given four sachets a day, three of which were dissolved
in milk using 7.5dl of milk per day and one in water (total: 3402kJ per day,
83.9g protein). Both programs met all recommendations for daily intake of
essential amino acids, fatty acids, vitamins and minerals. Daily intake of
vitamin D was 5mg, B12 vitamin was 2mg, iron was 14mg and calcium was
912mg in the VLED group. In the LED group, daily intake of vitamin D was
7.3mg, B12 vitamin was 6.4mg, iron was 19mg and calcium was 2146mg.
Daily intake of protein was at least 43.2g, and of essential fatty acids,
linoleic acid and linolenic acid was 3 and 0.4g, respectively. Dietary ﬁber
intake was 7.2g per day at minimum.
The second phase of the study consisted of 8 weeks’ hypo-energetic
diet program of B1200kcal per day (5040kJ per day) incorporating two
formula diet products daily. All participants were taught to make diet
plans with 5- -6 small meals a day. The principles of the diet were in line
with the guidelines for healthy eating issued by the Danish National Board
of Health, that is, low fat, low sugar and high ﬁber. The two daily diet
products supplied 3.4mg of vitamin D, 1.4mg of vitamin B12, 9.4mg of iron
and 608mg calcium. The aim and focus of the dietary education was to
modify long-term habitual eating patterns.
Variables
Body weight was measured on digital scales (TANITA BW-800, Frederiksberg
Vægtfabrik, Frederiksberg, Denmark). Other outcome measures were
changes in BMI calculated by a person’s weight (in kg) divided by the
square of his/her height (in m), where height was measured to the nearest
0.01m, blood-hemoglobin, plasma-parathyreoidea hormone (PTH), plasma-
25-OH-vitamin D3 (vitamin D), plasma-cobalamine (B12 vitamin) and plasma-
ferritin (iron). All were measured at baseline and at week 16. All blood samples
were analyzed at The Clinical Chemistry Department at Frederiksberg Hospital.
Plasma-25-OH-vitamin D3 was measured on a Abbot Architect ISR using
micro particle chemiluminescens immunoassay, plasma-cobalamine and
plasma-ferritin was measured on a Abbot Architect i2000SR using two
step immunoassay with chemiluminescens micro particle technology
and PTH was measured on a Cobas e601 using sandwich immunoassay
with chemiluminescens detection. Micronutrient deﬁciency was deﬁned
according to the references from the Clinical Chemistry Laboratory at
Frederiksberg Hospital: cutoff values were P-25-OH-vitamin D3 o50nmol/l,
P-cobalaminer o200pmol/l and P-ferritin o12mg/l. The rationale for
selecting these three micronutrients is that these three are linked to
important processes in the body, and both obesity as well as older age
increases the risk of deﬁciency. The cutoff value for too high levels of
PTH was 6.9pmol/l.
Lean body mass (LBM, kg), body fat (kg), BMD (g/cm
2) and BMC (g) were
determined by dual energy X-ray absorptiometry using a Lunar DPX IQ Full
Body Bone Densitometer (GE Medical Systems, Madison, WI, USA) and was
measured at baseline and after 16 weeks’ diet therapy. The cohort was
analyzed in total, as well as stratiﬁed by sex. The rationale for this is that
both blood levels of certain vitamins and minerals, as well as body
composition, are dependent on gender.
Statistics
The overall statistical analysis plan scrutinized the null hypothesis that
none of the outcome measures included had changed signiﬁcantly during
an intensive weight-loss program. Thus: H0 was DX¼0, which was tested
using 1-sample, paired t-tests. A priori we considered a P-value o0.05
(two-sided) as indicating a rejection of the null hypothesis. For sensitivity,
in order to support the results from the group level of the 1-sample t-tests,
we also applied Spearman’s correlation analyses to assess whether there
was an association between the weight change and subsequent change in
nutritional status and/or bone health on the level of the individual patient.
The SAS statistical package (version 9.2; SAS Institute Inc., Cary, NC, USA)
was used for all statistical analyses.
RESULTS
Of the 192 participants randomized to the trial, 175 (91%)
completed the study (returned for ﬁnal data collection at week
16). Only participants returning for the ﬁnal examination are
included in these analyses. The baseline characteristics of the
cohort are presented in Table 1.
The mean age of the participants (±s.d.) was 62.6±6.3 years.
The majority of the participants were women, which is typical for
knee osteoarthritis (142 of the 175). The mean weight at baseline
was 102.4±14.5kg, corresponding to a BMI of 37.1±4.4kg/m
2.
LBM was 50.6±8.7kg and fat mass was 46.6±9.2kg. The mean P-
25-OH-vitamin D3 was 48.9±20.1nmol/l at baseline with 84 (48%)
participants having lower values than 50nmol/l, which is the limit
for insufﬁciency, a threshold applied by the hospital laboratory.
The mean value of B12 at baseline was 293.2±120.1pmol/l;
34 (19.4%) participants had values below the recommended level
at 200pmol/l, a threshold applied by the hospital laboratory. The
mean ferritin was 117.1±94.6mg/l with two (1.1%) participants
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parathyroid hormone was 6.4±2.2pmol/l with 55 (31.4%)
participants having excessive values, that is, above 6.9pmol/l.
The mean BMC was 2780.7±462.5g and the mean BMD was
1.20±0.09g/m
2.
After the ﬁrst 8 weeks, the participants had lost 12.0kg (95%
conﬁdence interval (CI): 11.4--12.5kg; Po0.0001) and showed
statistically signiﬁcant increases in all three micronutrients (see
Appendix I). As illustrated in Figure 1, at week 16 the relative
change from baseline in the group of 175 participants was in favor
of the intensive weight loss program---having substantial improve-
ments in vitamin D (31.3%) and vitamin B12 (14.9%), with a
clinically relevant weight loss (13.7%) to a large extent because of
loss of fat mass (23.6%) rather than LBM (3.6%). The participants
had lost a mean of 14.0kg (95% CI: 13.3--14.7kg; Po0.0001). The
BMI was reduced by 5.1kg/m
2 (95% CI: 4.8--5.3kg/m
2; Po0.0001).
Sixty-two participants (35.4%) had a BMI o30kg/m
2 at week 16.
Table 2 shows the mean P-25-OH-vitamin D3 had increased with
15.3nmol/l (95% CI: 13.2--17.3nmol/l; Po.0001) at week 16 and
the number of participants with lower values than 50nmol/l had
fallen to 38 (21.7%). The mean value of vitamin B12 had increased
43.7pmol/l (95% CI: 32.1--55.4pmol/l; Po0.0001); with 21 (12%)
participants having values below the recommended level at
200pmol/l. Our study did not show any changes in mean ferritin,
and none of the participants presented ferritin values that were
below the normal range at week 16. Parathyroid hormone had
decreased with 0.87pmol/l (95% CI: 0.62--1.12; Po0.0001) and the
number of participants with values of PTH, which were too high
had fallen to 28 (16%). We did not ﬁnd any change in BMC
( 13.5g (95% CI:  33.3 to 6.2g; P¼0.18)). Being aware of that
BMC was a secondary outcome (amongst many), we cannot
exclude the possibility that this ﬁnding may be due to a type-2
error (see Ancillary analyses). Finally, there was a statistically
signiﬁcant decrease in the bone area of 20.5cm
2 (95% CI:  36.6 to
 4.5cm
2; P¼0.013) and an increase in BMD of 0.004g/cm
2 (95%
CI: 0.001 to 0.008g/cm
2; P¼0.025).
Ancillary analyses
Spearman’s correlation analyses were carried out to answer the
question concerning release of vitamin D bound in fat with weight
loss, on the individual patient rather than the group level, as fat is
a known storage location for vitamin D.
13 A strong correlation
between weight loss and vitamin D increase was found, whereas a
lesser, but still statistically signiﬁcant, correlation was seen
between fat loss and vitamin D increase (see Appendix II).
In order to prospectively explore whether it is reasonable to
accept the null hypothesis that the intensive weight loss does not
change the BMC level, we performed a prospective power analysis
under the assumption that 175 patients were in a new study (like
the present): For a paired t-test of a normal mean difference with a
two-sided signiﬁcance level of 0.05, assuming from Table 1 a
(conservative) common s.d. of 475g and correlation r¼0.95, a
sample size of 175 pairs has a power of 0.219 (that is, statistical
power o80%) to detect a mean difference of 13.5g. This is also
supported by the width of the 95% CIs, with the lower limit
( 33.3g) implying a potentially clinically relevant loss in BMC.
In a study concerning vitamin D one will always be aware of
possible differences in sun exposure with time of year, when in a
Northern country. Looking at this aspect in our population, we
Table 1. Demographic and clinical characteristics at baseline
Characteristic/variable Males (n¼33) Females (n¼142) Total (n¼175)
Age, years 62.4±6.4 (51- -74) 62.6±6.3 (50- -77) 62.6±6.3 (50- -77)
Height, cm 176.8±6.7 (168- -191) 163.8±6.2 (148- -184) 166.2±8.1 (148- -191)
Weight, kg 113.8±14.8 (88.5- -145) 99.8±13.2 (76- -144) 102.4±14.5 (76- -145)
Body mass index, kg/m
2 36.3±4.0 (31.0- -46.8) 37.2±4.5 (30.1--51.6) 37.1±4.4 (30.1- -51.6)
BMI 440kg/m
2, n (%) 5 (15.2) 30 (21.1) 35 (20.0)
B-haemoglobin, mmol/l 9.2±0.7 (7.3- -10.5) 8.6±0.6 (6.5--10.0) 8.7±0.6 (6.5- -10.5)
P-parathyroid hormone, pmol/l 5.3±1.6 (3.0- -12.1) 6.6±2.3 (2.5--14.6) 6.4±2.2 (2.5- -14.6)
P-parathyroid hormone 46.9pmol/l, n (%) 3 (9.1) 52 (36.6) 55 (31.4)
P-25-OH-vitamin D3, nmol/l 58.0±19.5 (10- -91) 46.7±19.7 (10- -92) 48.9±20.1 (10- -92)
P-25-OH-vitamin D3 o50nmol/l, n (%) 10 (30.3) 74 (52.1) 84 (48.0)
P-cobalamins (vitamin B12), pmol/l 274.7±100.5 (105- -509) 297.5±124.1 (94- -1159) 293.2±120.1 (94- -1159)
P-cobalamins (vitamin B12) o200pmol/l, n (%) 8 (24.2) 26 (18.3) 34 (19.4)
P-ferritin, ı `g/l 173.8±127.5 (12- -558) 103.9±80.2 (5- -533) 117.1±94.6 (5- -558)
P-ferritin o12ı `g/l, n (%) 0 (0.0) 2 (1.4) 2 (1.1)
Lean body mass, kg 65.2±6.5 (54.6- -78.4) 47.2±4.6 (37.1--59.5) 50.6±8.7 (37.1- -78.4)
Fat mass, kg 41.5±8.9 (30.7- -57.8) 47.8±8.9 (31.1--80.7) 46.6±9.2 (30.7- -80.7)
Bone area, cm
2 2659±207 (2202- -3051) 2232±185 (1837- -2773) 2312±253 (1837- -3051)
Bone mineral content, g 3384.1±473.1 (2151- -4134) 2640.5±329.0 (1931- -3840) 2780.7±462.5 (1931- -4134)
Bone mineral density, g/cm
2 1.27±0.11 (0.98- -1.46) 1.18±0.08 (0.94--1.43) 1.20±0.09 (0.94- -1.46)
Data are mean±s.d. and (min- -max), except when otherwise indicated. Dichotomous data are reported as number of observations and proportions (%).
Figure 1. Values are mean relative changes from baseline with
95% CI; deﬁned as Y¼[Xafter-Xbaseline]/Xbaseline combining data
from Tables 1 and 2.
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the groups who started treatment between January and April, and
the groups who started treatment between May and August. No
difference between the groups was found.
DISCUSSION
Our study showed that intensive weight loss achieved by use of a
low-energy formula diet was accompanied by signiﬁcant increases
in vitamin D and B12 levels. This is striking, as nearly half of our
participants had a deﬁciency of vitamin D at baseline and about
one in ﬁve showed deﬁciency in vitamin B12. At week 16, the
percentage of participants being deﬁcient in vitamin D and B12 had
decreased signiﬁcantly. The correction of these vitamin deﬁciencies
may very likely have been due to the formula products given, as the
product was enriched in both vitamin D and B12. However, some of
the vitamins responsible for the improvements, that is, vitamin D
may have been liberated from fat tissue during the weight loss.
13
The participants lost about 10% of their weight during this short
period of 16 weeks and as this weight loss was mainly due to
fat loss from fat stores, it could have been a source of vitamin D,
far larger than that given in the supplement.
14
The increase in vitamin D was paralleled by a decrease in PTH
(Pearson’s correlation coefﬁcient r¼0.21; Po0.01). One may
speculate if this was inﬂuencing the unchanged BMC and even
increased BMD during the program, a most interesting ﬁnding.
Measurement of BMD by DXA is the most widely used surrogate
marker of the bone status. However, using BMD to determine a
response to therapy may take 1--2 years.
15 From other weight loss
studies, changes in BMC and BMD has though been seen already
after 3 months.
16 Our results are in disagreement with earlier
studies with other weight loss programs, which led to decreased
BMC and BMD and accelerated bone turnover.
16- -19 In a calorie
restriction study by Redman et al., (2008) the participants were
offered diets providing the recommended daily intake of all
essential vitamins and minerals, and the participants did not
experience any negative effect on bone status with weight loss.
20
This supports that by making sure that the diet applied includes all
essential nutrients (like vitamin D and calcium) it is possible to
minimize or prevent loss from the muscle and bone. The formula
diet program provided at least 100% of the daily-recommended
intake of calcium and vitamin D for adults between 18 and 65
years of age at the time the study was conducted. The Danish
guidelines recommended a daily intake of vitamin D of 5mg and of
calcium 800mg. It has previously been shown that diets high in
calcium or dairy products can suppress bone resorption.
21,22 As
calcium absorption is dependent on the presence of 1.25 (OH)2
vitamin D, the requirement of calcium can only be meaningfully
discussed if the vitamin D status is sufﬁcient. The optimal vitamin
D intake is not known and there is evidence suggesting that the
present recommended intake is actually inadequate and needs to
be increased.
23 However, based on our data we can conclude that
the intake of both vitamin D and calcium was sufﬁcient to cause
an increase in BMD and to prevent loss of BMC. With their weight
loss, 460% of the participants experienced clinically signiﬁcant
improvements in pain and disability.
11 This could also have caused
an increase in physical activity and, if this was the case, increased
physical activity could explain the relatively low loss of LBM as well
Table 2. Changes and critical thresholds following intervention (16 weeks)
Characteristic/variable Males (n¼33) Females (n¼142) Total (n¼175)
DWeight, kg - -14.7 (- -16.9 to - -12.6) - -13.8 (--14.6 to - -13.1) - -14.0 (- -14.7 to --13.3)
Po0.0001
DBody mass index, kg/m
2 - -4.7 (- -5.4 to 4.0) - -5.2 (--5.4 to - -4.9) - -5.1 (- -5.3 to --4.8)
Po0.0001
BMI 440kg/m
2, n (%) 2 (6.0) 7 (4.9) 9 (5.1)
DB-haemoglobin, mmol/l - -0.20 (- -0.37 to - -0.04) 0.03 (--0.04 to 0.09) - -0.02 (- -0.08 to 0.04)
P¼0.61
DP-parathyroid hormone, pmol/l - -0.53 (- -0.98 to - -0.09) - -0.95 (--1.24 to - -0.66) - -0.87 (- -1.12 to --0.62)
Po0.0001
P-parathyroid hormone 46.9pmol/l, n (%) 4 (12.1) 24 (16.9) 28 (16.0)
DP-25-OH-vitamin D3, nmol/l 15.2 (9.9 to 20.4) 15.3 (13.0 to 17.5) 15.3 (13.2 to 17.3)
Po0.0001
P-25-OH-vitamin D3o50nmol/l, n (%) 4 (12.1) 34 (23.9) 38 (21.7)
DP-cobalamins, pmol/l 16.7 (- -8.8 to 42.1) 50.0 (37.0 to 63.0) 43.7 (32.1 to 55.4)
Po0.0001
P-cobalaminso200pmol/l, n (%) 6 (18.2) 15 (10.6) 21 (12)
DP-ferritin, mg/l - -18.7 (- -57.3 to 19.9) 12.2 (5.9 to 18.5) 6.4 (- -2.5 to 15.2)
P¼0.16
P-ferritino12mg/l, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
DLean body mass, kg - -2.2 (- -3.1 to - -1.2) - -1.7 (--2.2 to - -1.2) - -1.8 (- -2.3 to --1.3)
Po0.0001
DFat mass, kg - -11.0 (- -12.9 to - -9.0) - -11.0 (--11.6 to - -10.5) - -11.0 (- -11.6 to --10.4)
Po0.0001
DBone area, cm
2 - -32.1 (- -64.7 to 0.4) - -17.8 (--36.3 to 0.6) - -20.5 (- -36.6 to --4.5)
P¼0.013
DBone mineral content, g 16.4 (- -31.3 to 64.1) - -20.5 (--42.3 to 1.3) - -13.5 (- -33.3 to 6.2)
P¼0.18
DBone mineral density, g/cm
2 0.020 (0.011 to 0.030) 0.000 (--0.003 to 0.004) 0.004 (0.001 to 0.008)
P¼0.025
Data are mean values (95% conﬁdence interval; P-value associated with test for no change from baseline), except when otherwise indicated.
Dichotomous data are reported as number of observations and proportions (%).
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were though not advised to change their physical activity pattern
during the study, but were advised to stick to their usual routines.
Measurements of BMC and BMD by dual energy X-ray
absorptiometry are known to be affected, although to a minor
degree, by layer of excessive fat.
24 There are also differences
between dual energy X-ray absorptiometry scanners used. In
general, Hologic scanner measurements show an increase in BMD
whereas Lunar scanner measurements show a decrease in BMD
with weight loss.
24 In our study, we used a Lunar scanner (GE
Medical systems). Despite of this we found an increase in BMD
with weight loss. We therefore must conclude that this observa-
tion is real and if anything the increase in BMD is measured as too
low.
In this study we measured the blood levels of the micronu-
trients, we expected to be of clinical importance in relation to our
study population. However, it would have been interesting to
measure changes in a wider panel of micronutrients in connection
to this type of weight loss program, as it is well known that obesity
is often accompanied by a low status.
General implications
Obesity may be associated with nutrient deﬁciencies and the average
overweight subject may suffer from a nutritionally inadequate diet.
When trying to lose weight by consuming less food, individuals may
unwittingly reduce essential nutrient intake even further. This creates
an important role for nutrient-dense foods like formula diets, which
allow adequate intake of macro- and micronutrients although still
providing smaller amounts of energy. Given the growing rate of
obesity, it is important for subjects deciding to reduce their energy
intake to maintain a nutritionally sound diet, providing adequate
vitamins, minerals and macronutrients.
Our data suggest that weight loss can be achieved effectively
and safely with low-energy formula products, as long as this diet
contains a sufﬁcient amount of nutrients. This is supported by the
Look Ahead Study, where the number of meal replacements
consumed in the ﬁrst 6 months was signiﬁcantly related to weight
loss at week 26 (r¼0.32, Po0.001), as was the total number
consumed for the year to weight loss at week 52 (r¼0.30,
Po0.001).
25 As our obese patients need support to keep to a
healthy diet, the formula diet may take the burden of having to
deliberately choose the low-fat healthy option at each meal time,
and replacement of one or two meals a day with the low-calorie
formula diet may be the ‘medicine’, which helps the patients to
keep their micronutrients at acceptable levels as well as the
obtained weight loss on a more permanent scale.
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and fat mass (n¼175)
Characteristic/variable DWeight, kg DFat mass, kg
DP-25-OH-vitamin D3, nmol/l r¼ 0.21 r¼ 0.16
P¼0.006 P¼0.03
DP-cobalamins, pmol/l r¼0.08 r¼0.08
P¼0.28 P¼0.29
DP-ferritin, mg/l r¼ 0.33 r¼ 0.27
Po0.0001 P¼0.0003
DLean body mass, kg r¼0.39 r¼0.01
Po0.0001 P¼0.90
DFat mass, kg r¼0.82 r¼1.00
Po0.0001
DBone area, cm
2 r¼ 0.03 r¼0.22
P¼0.70 P¼0.003
DBone mineral content, g r¼0.02 r¼0.31
P¼0.82 Po0.0001
DBone mineral density, g/cm
2 r¼ 0.01 r¼0.12
P¼0.86 P¼0.11
Appendix I. Changes and critical thresholds following intervention (8 weeks)
Characteristic/variable Males (n¼33) Females (n¼142) Total (n¼175)
DWeight, kg  13.6 ( 15.4 to  11.8)  11.6 ( 12.2 to  11.1)  12.0 ( 12.5 to  11.4)
Po0.0001
DBody mass index, kg/m
2  4.3 ( 4.9 to  3.8)  4.3 ( 4.5 to  4.1)   4.3 ( 4.5 to  4.1)
Po0.0001
BMI 440kg/m
2, n (%) 2 (6.1) 8 (5.6) 10 (5.7)
DB-haemoglobin, mmol/l  0.20 ( 0.41 to 0.01) 0.16 (0.10 to 0.22) 0.08 (0.02 to 0.15)
P¼0.011
DP-parathyroid hormone, pmol/l  0.46 ( 1.03 to 0.10)  0.98 ( 1.26 to  0.70)  0.88 ( 1.14 to  0.63)
Po0.0001
P-parathyroid hormone 46.9pmol/l, n (%) 3 (9.1) 25 (17.6) 28 (16.0)
DP-25-OH-vitamin D3, nmol/l 16.6 (10.8 to 22.4) 15.5 (13.4 to 17.5) 15.7 (13.7 to 17.7)
Po0.0001
P-25-OH-vitamin D3 o50nmol/l, n (%) 4 (12.1) 38 (26.8) 42 (24)
DP-cobalamins, pmol/l 70.0 (40.9 to 99.1) 129.8 (113.0 to 146.6) 118.5 (103.5 to 133.5)
Po0.0001
P-cobalamins o200pmol/l, n (%) 3 (9.1) 6 (4.2) 9 (5.1)
DP-ferritin, mg/l 5.7 ( 32.9 to 44.3) 35.5 (26.7 to 44.3) 29.9 (19.8 to 40.0)
Po0.0001
P-ferritin o12mg/l, n (%) 0 (0.0) 1 (0.7) 1 (0.6)
Data are mean values (95% conﬁdence interval; P-value associated with test for no change from baseline), except when otherwise indicated.
Dichotomous data are reported as number of observations and proportions (%).
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